tirzepatide sleep apnea fda approval New weight-loss treatment becomes first FDA-approved drug for ZEPBOUND (Tirzepatide) FDA-Approved for Obstructive

In addition, 50% to 57% of patients achieved a weight reduction of 20% or more (with the 10 to 15 mg dose) as compared to 3% in the placebo group

On the back of that news, Novo rallied from late2025 lows of around 45 dollars to roughly 64 dollars ahead of February earnings

Concerning entero-pancreatic signaling, or crosstalk, between microbiota and the pancreas, local, as opposed to systemic, GABA levels are likely more relevant to autoimmune diabetes (107)

Companies like Sandoz and Apotex are expected to launch generic versions of semaglutide in Canada next year

Dias V, Junn E, Mouradian MM

Nagai Y, Hashimoto E, Oikawa R, et al